首页 | 本学科首页   官方微博 | 高级检索  
检索        

三苯双脒肠溶片治疗899例儿童肠道线虫感染的临床观察
引用本文:肖树华,吴中兴,张剑辉,王善清,王世海,邱东川,王翀.三苯双脒肠溶片治疗899例儿童肠道线虫感染的临床观察[J].中国寄生虫学与寄生虫病杂志,2007,25(5):372-375.
作者姓名:肖树华  吴中兴  张剑辉  王善清  王世海  邱东川  王翀
作者单位:1. 中国疾病预防控制中心寄生虫病预防控制所,世界卫生组织疟疾、血吸虫病和丝虫病合作中心,上海,200025
2. 江苏省寄生虫病防治研究所,无锡,214064
3. 山东新华制药股份有限公司,淄博,255005
4. 海南省疾病预防控制中心,海口,570203
5. 贵州省疾病预防控制中心,贵阳,550001
6. 四川省疾病预防控制中心,成都,610031
摘    要:目的 评价三苯双脒肠溶片(200 mg)治疗4~14岁儿童钩虫和蛔虫感染者的安全性和疗效。 方法 在海南、四川和贵州等3个临床试验中心进行三苯双脒肠溶片开放临床试验,受治者用改良加藤法(Kato-Katz)粪检确诊为钩虫、蛔虫感染,钩虫与蛔虫混合感染或合并鞭虫感染等,共收治4~14岁儿童899例,采用三苯双脒肠溶片200 mg单剂口服治疗,观察不良反应,并于治疗后3~4周用相同方法作粪检评价治疗效果。 结果 三苯双脒肠溶片200 mg对儿童钩虫感染的治愈率及有效率分别为82.0%(433/528)和99.2%(524/528);对蛔虫感染的治愈率及有效率分别为90.1%(576/639)和99.7%(637/639),而鞭虫感染治愈率仅为36.8%(112/304)。儿童顿服三苯双脒肠溶片200 mg的不良反应轻微和短暂,总的不良反应率为1.6%(14/899),主要为头晕、恶心和呕吐等。血、尿常规,肝、肾功能和心电图检查未见明显影响。 结论 三苯双脒肠溶片200 mg治疗儿童钩虫和蛔虫感染的疗效显著,不良反应率低。

关 键 词:三苯双脒  钩虫  蛔虫  鞭虫  疗效  安全性
文章编号:1000-7423(2007)-05-0372-04
收稿时间:2007-07-22
修稿时间:2007年7月22日

Clinical Observation on 899 Children Infected with Intestinal Nematodesand Treated with Tribendimidine Enteric Coated Tablets
XIAO Shu-hua,WU Zhong-xing,ZHANG Jian-hui,WANG Shan-qing,WANG Shi-hai,QIU Dong-chuan,WANG Chong.Clinical Observation on 899 Children Infected with Intestinal Nematodesand Treated with Tribendimidine Enteric Coated Tablets[J].Chinese Journal of Parasitology and Parasitic Diseases,2007,25(5):372-375.
Authors:XIAO Shu-hua  WU Zhong-xing  ZHANG Jian-hui  WANG Shan-qing  WANG Shi-hai  QIU Dong-chuan  WANG Chong
Institution:1 NatiNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collab -orating Centre for Malaria, Schistosomiasis and Filariasis, Shanghai 200025, China ; 2 Jiangsu Provincial Institute of Parasitic Diseases, Wuxi 214064, China; 3 Shandong Xinhua Pharmaceutical Company, Limited, Zibo 255005, China; 4 Hainan Provincial Center for Disease Control and Prevention, Haikou 570203, China; 5 Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China; 6 Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610031, China
Abstract:Objective To evaluate the efficacy and safety of tribendimidine in treatment of children with hookworm and Ascaris lumbricoides infections. Methods An open and multi-center clinical trial was conducted in the provinces of Hainan, Sichuan and Guizhou. 899 children aged 4-14 years were enrolled in the study. Hookworm, A. lumbircoides or other helminth infections were diagnosed by improved Kato-Katz method. All the patients were treated orally with tribendimidine enteric coated tablet at a single dose of 200 mg. The efficacy was evaluated by stool examination 3-4 weeks post treatment. Results The cure rate and effective rate of the children with hookworm infection were 82.0%(433/528) and 99.2%(524/528), respectively, while in children with A.lumbricoides infection, they were 95.0%(576/639) and 99.8%(637/639), respectively. The efficacy of tribendimidine enteric coated tablet given to the children with Trichuris trichiura infection at a single dose of 200 mg was 36.8%(112/304). The adverse effect induced by tribendimidine, such as dizziness, nausea and vomiting, was light and transient with an adverse effect rate of 1.6% (14/899). No apparent impact was seen on the blood and urine routine examination, hepatic and renal function as well as ECG examination. Conclusion Tri-bendimidine given at a single dose of 200 mg exhibits lower adverse effect rate and potential efficacy in the treatment of children with hookworm and A.lumbricoides infections.
Keywords:Tribendimidine  Hookworm  Ascaris lumbricoides  Trichuris trichiura  Efficacy  Safety
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国寄生虫学与寄生虫病杂志》浏览原始摘要信息
点击此处可从《中国寄生虫学与寄生虫病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号